Updates

("Par Registered Office : 815, Nilamber Triumph, Gotri-Vasna Road, Vadodara -390 007. Gujarat (INDIA). Ph.: +91-265-2991021 / 2991022 DRUGS AND CHEMICALS LIMITED Email: admin@pardrugs.com CIN No.: L24117GJ1999PLC035512 PAR/CS/NSE/2026-27/11 ---------- www pardrugs com Date: 08/08/2026 The Manager Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai-400 051 Maharashtra Subject: Outcome of the Board Meeting held on Saturday, 8th day of August, 2026 in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 Ref.: Symbol-PAR, ISIN: INE04LG01015 Dear Sir/Madam, The meeting of Board of Directors of the Company held on Saturday, 8th day of August, 2026 at 3:30 P.M. through Video Conferencing ("VC") mode to transacted the following business: Item No. Outcomes 1. After the recommendation of Audit Committee, the Board of Directors considered, approved and took on record the Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2026 along with Limited Review Report given CA Mira! Mehta, Partner of Sarupria Somani & Associates, Chartered Accountants, Statutory Auditor of the Company. The Board authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbhai Savani, CEO & Director (DIN: 00198203) to sign the approved financial results.The financial results were duly reviewed by Audit Committee at its meeting. Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the Certificate of correctness was placed before the Board Meeting. (Limited Review Report with Financials statements and Certificate of Correctness are attached as Annexure) 2. The Board considered and approved the drafts of advertisements to be published in newspapers regarding Unaudited Standalone Financial Results of the Company for the quarter ended on 30th June, 2026. The Board decided to publish the said advertisements in the Economic Times & Navgujarat Samay or as available. 3. The Board took note of Investor grievances report for the quarter ended 30th June, 2026 and reviewed the SCORES platform of SEBI to solve the investor compliant till date. 4. The Board took note and review the Corporate Governance Report of the Company for the quarter ended 30th June, 2026. 5. After recommendation of Audit Committee, the Board considered and approved the Policy on Communication between Statutory Auditor and Those Charged with Governance (TCWG), which will be available at the website of the Company at www.pardrugs.com with due course. Page 1 of 3 ("Par Registered Office : 815, Nilamber Triumph, Gotri-Vasna Road, Vadodara -390 007. Gujarat (INDIA). Ph.: +91-265-2991021 / 2991022 DRUGS AND CHEMICALS LIMITED Email: admin@lpardrugs.com CIN No.: L24117GJ1999PLC035512 With the permission and consent of the Chairman & all other Board members following other matter was taken and approved 6. By considering the suggestion of audit committee, the board has considered, discussed, approved to avail the forward booking Banking facilities by Company from ICICI Bank and authorized Mr. Falgun V. 5avani, Chairman and Managing Director (DIN: 00198236) and/or Mr. Jignesh Vallabhbhai 5avani, CEO & Director (DIN: 00198203) of the Company to provide required resolution to the Bank and be and are hereby authorized to do sign and/digitally sign all such necessary forms, documents, papers, and to do all such acts, matters, deeds as may be required for the above mentioned purpose. Further, the Board authorised any of the director to provide required certified true copy of resolutions to give effect for the mentioned matter. 7. By considering the suggestion of audit committee, the board has considered, discussed, approved to appoint NEO Alternative Asset Managers Private Limited (SEBI Regis~ration No.: INP000007641) as a Portfolio Manager of the Company to avail Portfolio Management and other Services and to open demat account with them. The Board authorised Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236) and Mr. Jignesh Vallabhbhai Savani, CEO & Director (DIN: 00198203) to sign and/digitally sign, execute all such necessary documents including application forms, agreements, undertakings, indemnities, Power of Attorney, documents, operate demat and/or give instruction to operate Demet on behalf of the Company and to do all such acts, deeds and things as may be necessary and incidental thereto for the purpose of giving effect. Further, the Board authorised any of the director to provide required certified true copy of resolutions to give effect for the mentioned matter. 8. By considering the suggestion of audit committee, the Board of Directors has discussed and approved to sale of Motor Vehicle of Company at total of Rs 3.60 Lakh approx. and to purchase of New Motor Vehicles (i) Toyota Fortuner Legender 4X2 (AT) Diesel pearl white & black variant amounting of ex-showroom Price of Rs. 42.92 Lakh plus applicable taxes, insurance, accessories, warranties and others charges in the name of Par Drugs And Chemicals Limited for the use of Mr. Jignesh V. Savani ,Director & CEO (DIN: 00198203) of the Company. (ii) Mahindra XEV 9E PACK-3 B-79 ruby velvet variant amounting of ex-showroom Price of Rs. 29.43 Lakh plus applicable taxes, insurance, accessories, warranties and others charges in the name of Par Drugs And Chemicals Limited for the use of Mr. Falgun V. Savani, Chairman and Managing Director (DIN: 00198236). The Board authorised any of the current directors to sign and execute all such necessary forms, documents, agreement, papers, and to do all such acts, matters and deeds as may be required time to time for the sale & purchase of the motor vehicles. Although all the submission is made by integrated financial in XBRL format, this intimation shall also be considered as Integrated Filing (Financial) for the quarter ended on 30th June, 2026 pursuant to Master Circular No. HO/49/14/14(7)2025-CFD-POD2/l/3762/2026 dated January 30, 2026 QUARTERLY INTEGRATED FILING (FINANCIAL) FOR THE QUARTER ENDED JUNE 30, 2026 PARTICULARS DISCLOSURE A. FINANCIAL RESULTS Enclosed Page 2 of 3 ("Par Registered Office : 815, Nilamber Triumph, Gotri-Vasna Road, Vadodara -390 007. Gujarat (INDIA). Ph. : +91-265-2991021 / 2991022 DRUGS AND CHEMICALS LIMITED Email: admin(@pardrugs.com CIN No.: L24117GJ1999PLC035512 --------------------------------------------- wwwpardrugs.com B. STATEMENT ON DEVIATION OR VARIATION Not Applicable FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED Reason of Non-A1212licabilitll: As there is no any INSTITUTIONS PLACEMENT ETC. proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. C. OUTSTANDING DEFAULT ON LOANS AND Not Applicable DEBT SECURITIES Reason of Non-A1212llcabilitl£: As there is no any outstanding default on loans and debt securities. D. DISCLOSURE OF RELATED PARTY Not Applicable TRANSACTIONS Reason of Non-A1212licabilitll: As per above mentioned circular applicable only for half-yearly filings i.e 2nd and 4th quarter. Hence, not applicable for the Quarter ended June 30, 2026. E. STATEMENT ON IMPACT OF AUDIT Not Applicable QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG- Reason of Non-A1212licabilitl£: As per above mentioned WITH ANNUAL AUDITED FINANCIAL RESULTS circular applicable only for Annual Filing i.e., 4th quarter. Hence, not applicable for the Quarter ended June 30, 2026. Further, with reference to our intimation dated 25th June, 2026 and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and amendment made time to time till date and according to Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for trading in securities of the Company will be opened after 48 hours of de [Showing first 8,000 characters — download PDF for full document]